Quantum computing is becoming a new focus for tech sector investors. D-Wave's approach to building quantum computers differs from most of its competitors. While the company has achieved a bit of ...

MIT researchers have developed a new method for designing 3D structures that can be transformed from a flat configuration ...

D-Wave is a promising pure play, but Alphabet's resources could position it to be a bigger quantum-computing winner. D-Wave Quantum has been making waves in the quantum-computing space. The company's ...

D-Wave stock is up nearly 500% in the past 12 months. The company announced a new government business unit in December. Much of the stock's meteoric rise has been due to overall market hype for ...

D-Wave Quantum and Alphabet are pursuing technology to elevate artificial intelligence (AI) to new heights. D-Wave's quantum computers can provide potent computational power to AI systems, but Q3 ...

D-Wave Quantum stock has gained over 2,400% since November 2024 but is down 40% from its peak in October. It's too early to pick winners in the quantum computing race, even in the less crowded quantum ...

D-Wave Quantum (NYSE: QBTS) calls itself "a leader in the development and delivery of quantum computing systems, software, and services." Investors seem to agree. Since the start of 2025, D-Wave stock ...

Quantum computing has emerged as a hot new item on Wall Street, and for good reason: Supporters say it could usher in a technological revolution. While behemoths like International Business Machines ...

D-Wave has seen incredible valuation gains in conjunction with rising interest in quantum computing. The company has been posting encouraging sales growth, but trades at a highly growth-dependent ...

Event to showcase D-Wave’s award-winning quantum technology and its ability to solve problems beyond the reach of classical with real-world customer success stories Company to share latest product ...

Wave Life Sciences Ltd. (NASDAQ: WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE ...